Evidence map›Paper›PMID 29371474›Full record

ArticleThe oncologist2018

Mutant

Ruth Perets, Orli Greenberg, Talia Shentzer, Valeria Semenisty, Ron Epelbaum, Tova Bick, Shada Sarji, Ofer Ben-Izhak, Edmond Sabo, Dov Hershkovitz

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05400681 unknown statusnot on this mapstarted 2020, after this paper: background citation

Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer

Typeobservational_patient_registrySponsorSonke DetlefsenRan2020 to 2024Enrolled200ConditionsPancreatic Cancer, Pancreatic Adenocarcinoma
NCT06807112 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Influence of Secretin Stimulated Pancreatic Secretion on Circulating Tumor DNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma

TypeobservationalSponsorCharles University, Czech RepublicRan2025 to 2027Enrolled39ConditionsPancreatic Adenocarcinoma, Pancreatic CancerArmsIntravenously administered secretin
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruth PeretsDepartments of Oncology.
Orli GreenbergDepartment of Pathology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Talia ShentzerDepartments of Oncology.
Valeria SemenistyDepartments of Oncology.
Ron EpelbaumDepartments of Oncology.
Tova BickPathology, Rambam Health Care Campus, Haifa, Israel.
Shada SarjiPathology, Rambam Health Care Campus, Haifa, Israel.
Ofer Ben-IzhakPathology, Rambam Health Care Campus, Haifa, Israel.
Edmond SaboPathology, Rambam Health Care Campus, Haifa, Israel.
Dov HershkovitzDepartment of Pathology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel dovh@tlvmc.gov.il.ORCID 0000-0002-7954-4486

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany new pancreatic cancer treatment combinations have been discovered in recent years, yet the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains grim. The advent of new treatments highlights the need for better monitoring tools for treatment response, to allow a timely switch between different therapeutic regimens. Circulating tumor DNA (ctDNA) is a tool for cancer detection and characterization with growing clinical use. However, currently, ctDNA is not used for monitoring treatment response. The high prevalence of SUBJECTS, MATERIALS, AND

methodsSeventeen metastatic PDAC patients were recruited and serial plasma samples were collected. CtDNA was extracted from the plasma, and

resultsPlasma

conclusionOur results confirm that mutant IMPLICATIONS FOR PRACTICE: Avoiding futile chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) patients by monitoring response to treatment is of utmost importance. A novel biomarker for monitoring treatment response in PDAC, using mutant

Indexed as

MutationAgedBiomarkers, TumorCarcinoma, Pancreatic DuctalCirculating Tumor DNAFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPrognosisProto-Oncogene Proteins p21(ras)Biomarkers, TumorCirculating Tumor DNAKRAS protein, humanProto-Oncogene Proteins p21(ras)AdenocarcinomaCancer monitoringCirculating tumor DNAKRASLiquid biopsyPancreatic cancer

Identifiers

PMID29371474
PMCPMC5947453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.